Newronika secures €13.6M Series B for Parkinson's DBS development

Newronika has successfully closed a €13.6 million ($14.1 million) Series B funding round led by Fondazione ENEA Tech e Biomedical, with participation from several existing investors. The funds will support the clinical validation and commercialization of Newronika's adaptive deep brain stimulation (DBS) system, which aims to improve symptom relief and reduce side effects for Parkinson’s disease patients. The company plans to use this capital to advance its product pipelines, recruit talent, and establish strategic collaborations. Recently, Newronika received FDA investigational device exemption (IDE) approval to conduct trials comparing its adaptive DBS system against conventional methods. The adaptive platform utilizes real-time neural data to optimize therapy, representing a significant innovation in neuromodulation. CEO Dr. Lorenzo Rossi emphasized that this funding validates their commitment to transforming DBS delivery through integration of advanced technology.